Optical Biopsy and Fallopian Tube
Optical Biopsy and Fallopian Tube
High-grade serous ovarian cancer is the most threatening type of gynaecological cancer with
 an important mortality due to late diagnosis. However the prognosis is excellent in the early
 stages of the disease. Recently it has been described a new serous carcinogenic sequence from
 the fallopian tube with tubal precancerous lesions. Therefore the identification of these
 early preinvasive lesions would be of great interest in the population with hereditary
 predisposition for ovarian cancer (concept of oncofertility) and in the general population
 (to determine whether bilateral salpingectomy has to be performed during a hysterectomy for
 benign disease).

 The optical biopsy has been developed and validated in the detection of early precancerous
 lesions (such as Barrett's oesophagus or in situ cancer of the bladder). The first objective
 of this study is to prospectively assess the efficacy of optical biopsy (Cellvizio®) in the
 study of fallopian tubes during laparoscopy with correlation between the histopathological
 and immunohistochemical analysis and the endomicroscopy image interpretation. The second
 objective is to describe the optical biopsy pictures in order to state a classification.
Inclusion Criteria:

 -  Woman aged 18 years or more

 -  All patients with laparoscopic salpingectomy for benign conditions (tubal ligation,
 during a hysterectomy), for prophylactic conditions (BRCA mutation) or in case of pelvic
 cancers

 -  Informed and signed consent

 Exclusion Criteria:

 -  Interview revealing disorder entailing unacceptable risk of postoperative complications:
 coagulation disorder, immune system disorder, evolutive disease, etc.

 -  Pregnancy, ongoing or planned during the study period

 -  Allergy to fluorescein

 -  Previous allergy or anaphylactic shock during an angiography

 -  Allergic or hypersensibility reactions

 -  Severe asthma, chronic cardiac or pulmonary diseases

 -  Restricted renal function

 -  Patient under a beta-blockers treatment

 -  Inability to understand information provided

 -  Not covered by a national health insurance scheme, prisoner or under administrative
 supervision
Inclusion Criteria:

 -  Woman aged 18 years or more

 -  All patients with laparoscopic salpingectomy for benign conditions (tubal ligation,
 during a hysterectomy), for prophylactic conditions (BRCA mutation) or in case of
 pelvic cancers

 -  Informed and signed consent

 Exclusion Criteria:

 -  Interview revealing disorder entailing unacceptable risk of postoperative
 complications: coagulation disorder, immune system disorder, evolutive disease, etc.

 -  Pregnancy, ongoing or planned during the study period

 -  Allergy to fluorescein

 -  Previous allergy or anaphylactic shock during an angiography

 -  Allergic or hypersensibility reactions

 -  Severe asthma, chronic cardiac or pulmonary diseases

 -  Restricted renal function

 -  Patient under a beta-blockers treatment

 -  Inability to understand information provided

 -  Not covered by a national health insurance scheme, prisoner or under administrative
 supervision